Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
“The presentation at ASN represents current data from the EQUALISE study, which includes all but the last patient in the follow up period,” said Bruce Steel, chief executive officer at Equillium.
- “The presentation at ASN represents current data from the EQUALISE study, which includes all but the last patient in the follow up period,” said Bruce Steel, chief executive officer at Equillium.
- “We are encouraged that we continue to see clinically meaningful response rates, particularly in these highly proteinuric subjects.
- Results are comparable to those observed in the Phase 3 AURORA1 study of voclosporin (ORR 70% at 6 and 12 months in active treatment).
- Consistent with the decline in UPCR overtime, subjects were able to taper their systemic corticosteroids over the course of the study.